La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Navidea Biopharmaceutical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Navidea Biopharmaceutical..

Navidea Biopharmaceutical (OTC:NAVB) Azioni, Catena delle Opzioni

Navidea Biopharmaceutical

Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

NAVIDEA BIOPHARMS INC by Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals Inc

News

NAVB

Navidea Biopharmaceuticals Faces Trading Suspension As NYSE American Panel Upholds Decision; Anticipates Move To OTC Markets

NYSE American To Suspend Trading In Navidea Biopharmaceuticals

<h3>Gainers</h3>
<ul>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.</li>
<li>Tharimmune Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares rose 101.4% to $0.4450 in pre-market trading after falling around 5% on Monday.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares gained 31.1% to $0.1709 in pre-market trading. Infobird recently announced receipt of delinquency notification letter from the Nasdaq.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) gained 19.3% to $0.1945 in pre-market trading after jumping over 36% on Monday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose).</li>
<li>Akumin Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aku#NASDAQ">AKU</a>) shares rose 18.4% to $0.1670 in pre-market trading.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) shares surged 17% to $0.2399 in pre-market trading.</li>
<li>Precision BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtil#NASDAQ">DTIL</a>) rose 16.1% to $0.4280 in pre-market trading.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) shares climbed 13.8% to $5.78 in pre-market trading. Adaptive recently announced the launch of Epic integration for clonoSEQ.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) shares jumped 11.7% to $1.05 in pre-market trading.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) rose 10.3% to $0.2560 in pre-market trading after dipping 20% on Monday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) fell 67.8% to $0.8195 in pre-market trading after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.</li>
<li>Murphy Canyon Acquisition Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cdt#NYSE">CDT</a>) fell 18.1% to $8.50 in pre-market trading after dipping 38% on Monday.</li>
<li>Jet.AI Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jtai#NASDAQ">JTAI</a>) shares fell 17.6% to $2.53 in pre-market trading after surging 25% on Monday.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares fell 13.5% to $0.1751 in pre-market trading after declining around 15% on Monday.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) fell 13.2% to $1.38 in pre-market trading. Biophytis shares jumped over 72% on Monday after the company and Skyepharma announced a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) fell 12.4% to $0.1086 in pre-market trading after surging 40% on Monday.</li>
<li>Sacks Parente Golf, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spgc#NASDAQ">SPGC</a>) fell 11.7% to $1.20 in pre-market trading. The company recently posted a narrower second-quarter loss.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) shares fell 10.4% to $0.1720 in pre-market trading after jumping 25% on Monday.</li>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) fell 10% to $0.28 in pre-market trading after gaining 5% on Monday.</li>
<li>Navidea Biopharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/navb#NYSE">NAVB</a>) fell 9.8% to $0.0833 in pre-market after declining over 4% on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/09/34893911/td-synnex-profound-medical-and-3-stocks-to-watch-heading-into-tuesday"> TD SYNNEX, Profound Medical And 3 Stocks To Watch Heading Into Tuesday</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

AVTX

BPTS

BSFC

DTIL

FAZE

FEMY

IFBD

JTAI

LIFW

NEXI

PXMD

RNAZ

SPGC

THAR

Why Femasys Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket

Gainers
Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) shares jumped 124.2% to $0.1697 after falling 15% on Monday.
Avinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgr#NASDAQ">AVGR</a>) gained 63.9% to $9.95, adding to outsized gains from Monday. On Monday, Avinger shares soared 46.8% after the company announced the commercial launch of its Tigereye ST image-guided CTO crossing device.
Sezzle Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sezl#NASDAQ">SEZL</a>) shares climbed 46.6% to $18.95.
PHAXIAM Therapeutics S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phxm#NASDAQ">PHXM</a>) rose 30% to $5.17.
Elutia Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elut#NASDAQ">ELUT</a>) shares gained 29.1% to $1.6006 after the company announced the sale of its Orthobiologics business unit to Berkeley Biologics LLC. Elutia announced $26 million private placement of 7,355,869 shares of common stock at $1.4275 per share.
Orchestra BioMed Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/obio#NASDAQ">OBIO</a>) surged 24.4% to $10.50. The FDA granted an investigational device exemption to initiate BACKBEAT Study evaluating Orchestra biomed&#39;s atrioventricular interval modulation therapy (BACKBEAT CNT) for hypertensive patients who are indicated for a dual-chamber cardiac pacemaker.
Rackspace Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxt#NASDAQ">RXT</a>) gained 20.2% to $1.78 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $3.5 price target.
Eos Energy Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eose#NASDAQ">EOSE</a>) jumped 16.6% to $2.65.
Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) rose 15% to $5.32 after falling 18% on Monday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction.
Solowin Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swin#NASDAQ">SWIN</a>) climbed 14.8% to $2.3882.
Navidea Biopharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/navb#NYSE">NAVB</a>) gained 13.5% to $0.1048.
Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) shares rose 13.2% to $0.2158. Galera scheduled a Type A meeting with the FDA to discuss next steps for its radiotherapy avasopasem.
Lichen China Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/licn#NASDAQ">LICN</a>) gained 11.6% to $1.15.
TriSalus Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlsi#NASDAQ">TLSI</a>) jumped 11.4% to $5.85.
Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>) gained 10% to $9.48.
SelectQuote, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slqt#NYSE">SLQT</a>) rose 9.6% to $1.2395. Selectquote COO William Grant, III reported purchase of 150,000 shares at an average price of $1.20 per share in Form 4 filing on Monday.
Conduent Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cndt#NASDAQ">CNDT</a>) gained 9.4% to $3.3703. Conduent and HealthEquity announced that they have entered into a definitive agreement to transfer BenefitWallet&#39;s Health Savings Account (HSA) portfolio to HealthEquity.
Stem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stem#NYSE">STEM</a>) gained 8.6% to $4.88. Stem expanded its India Center Of Excellence, aimed at fostering global growth, optimizing operations, and increasing customer value.
Waldencast plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wald#NASDAQ">WALD</a>) jumped 7.3% to $9.41.
Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) gained 5% to $25.48. Semtech Director Paul V. Walsh Jr. acquired a total of 20,000 shares at an average price of $24.83.
Losers
Digital Transformation Opportunities Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtoc#NASDAQ">DTOC</a>) shares fell 34.5% to $19.00 after jumping 173% on Monday.
Histogen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsto#NASDAQ">HSTO</a>) fell 32.9% to $0.4419 as the company reported board approval of complete liquidation and dissolution.
Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) declined 26% to $12.27 after the company issued corporate update at Investor Day. Revance Therapeutics estimates total non-cash impairment charges from goodwill and other assets to be between an estimated $80 million and $100 million.
Novo Integrated Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvos#NASDAQ">NVOS</a>) shares fell 26% to $0.2517 after declining 15% on Monday.
Axcella Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axla#NASDAQ">AXLA</a>) declined 24.5% to $11.32.
MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) fell 23.8% to $0.0931 after dipping 35% on Monday.
Terran Orbital Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/llap#NYSE">LLAP</a>) fell 19.4% to $1.1450 after the company priced its previously announced public offering of 23.2 million shares and warrants to purchase up to 23.2 million shares at a combined public offering price of $1.40 per share and accompanying warrant.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtp#NASDAQ">SXTP</a>) shares fell 18.9% to $0.90 after the company said it has withdrawn its COVID Phase IIB investigational new drug and announced plans to resubmit pending assessment of ability to meet FDA requirements.
SCWorx Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/worx#NASDAQ">WORX</a>) fell 18.5% to $0.2130 after jumping 38% on Monday.
T2 Biosystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttoo#NASDAQ">TTOO</a>) fell 17.4% to $0.3796. T2 Biosystems shares gained over 65% on Monday after the FDA cleared the company&#39;s biothreat panel for commercial distribution.
Equinox Gold Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eqx#NYSE">EQX</a>) shares slipped 17% to $4.3499 after the company reported a bought deal offering of convertible senior notes.
Perspective Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/catx#NASDAQ">CATX</a>) fell 15.2% to $0.2711 after jumping 56% on Monday.
Ebix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebix#NASDAQ">EBIX</a>) fell 14% to $11.27.
Aurora Innovation, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aur#NASDAQ">AUR</a>) declined 13.6% to $3.0670. TD Cowen initiated coverage on Aurora Innovation with a Market Perform rating and announced a price target of $3.
Amprius Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ampx#NYSE">AMPX</a>) fell 11.2% to $4.4650. The company announced it will showcase its new silicon nanowire battery manufacturing line on Dec. 14.
Cardlytics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdlx#NASDAQ">CDLX</a>) declined 10.9% to $14.56.
NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) shares fell 10.4% to $9.23 after the company announced a proposed offering of $1 billion convertible senior notes.
ProKidney Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prok#NASDAQ">PROK</a>) dipped 10.3% to $5.77.
Vasta Platform Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsta#NASDAQ">VSTA</a>) fell 9.9% to $3.5767.
TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) fell 9.7% to $1.4526.
Rocket Lab USA, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rklb#NASDAQ">RKLB</a>) shares fell 9.2% to $4.5775 as the company&#39;s 41st mission succumbs to technical issues, prompting it to postpone its next mission and revise its third-quarter guidance.
Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) declined 8.5% to $47.53.
Nanobiotix S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbtx#NASDAQ">NBTX</a>) fell 7.6% to $8.36.
Arm Holdings plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arm#NASDAQ">ARM</a>) fell 5% to $55.08 amid post-<a href='https://www.benzinga.com/news/ipos'>IPO</a> volatility. Redburn Atlantic initiated coverage on the stock with a Neutral rating and a $50 price target.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34609563/wall-streets-most-accurate-analysts-say-buy-these-3-tech-stocks-with-over-3-dividend-yie"> Wall Street&#39;s Most Accurate Analysts Say Buy These 3 Tech Stocks With Over 3% Dividend Yields</a>

Intraday Update

AMPX

AVGR

AXLA

CATX

CDLX

CNDT

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CVNA

DTOC

EBIX

ELUT

EOSE

GRTX

HSTO

IRWD

LICN

LLAP

NBTX

NEPT

NVOS

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PHXM

PROK

RKLB

RVNC

SEZL

SLQT

SMTC

STEM

SWIN

SXTP

TLSI

TTOO

VSTA

WALD

WORX

Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron Inc. - Subscription Right (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVNR#NASDAQ">LGVNR</a>) shares increased by 172.7% to $0.01 during Tuesday's pre-market session. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 47.61% to $8.96. The company's market cap stands at $6.4 million. </li>
<li>Navidea Biopharmaceutical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAVB#AMEX">NAVB</a>) shares increased by 22.75% to $0.11. The market value of their outstanding shares is at $11.3 million. </li>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) stock increased by 22.58% to $1.52. The company's market cap stands at $24.6 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock rose 19.81% to $1.27. The market value of their outstanding shares is at $5.0 million. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock increased by 19.69% to $0.79. The market value of their outstanding shares is at $61.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>UpHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPH#NYSE">UPH</a>) stock declined by 50.0% to $0.49 during Tuesday's pre-market session. The company's market cap stands at $8.4 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares decreased by 28.13% to $0.83. The market value of their outstanding shares is at $4.8 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 15.45% to $0.39. The company's market cap stands at $129.4 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 13.2% to $0.23. The company's market cap stands at $3.7 million. </li>
<li>Kinnate Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNTE#NASDAQ">KNTE</a>) stock fell 12.93% to $1.48. The market value of their outstanding shares is at $69.7 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares declined by 9.99% to $0.11. The company's market cap stands at $36.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

AKLI

KNTE

LGVNR

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) stock moved upwards by 108.7% to $0.91 during Thursday's pre-market session. The market value of their outstanding shares is at $6.4 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock moved upwards by 34.1% to $0.3. The market value of their outstanding shares is at $6.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares rose 22.22% to $1.1. The company's market cap stands at $2.2 million. </li>
<li>Navidea Biopharmaceutical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAVB#AMEX">NAVB</a>) shares moved upwards by 20.6% to $0.14. The market value of their outstanding shares is at $14.0 million. </li>
<li>Longeveron Inc. - Subscription Right (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVNR#NASDAQ">LGVNR</a>) stock rose 14.94% to $0.01. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares increased by 14.85% to $1.16. The company's market cap stands at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock declined by 46.3% to $1.75 during Thursday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock fell 21.79% to $1.4. The company's market cap stands at $11.4 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 16.04% to $1.1. The market value of their outstanding shares is at $4.0 million. </li>
<li>Impel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPL#NASDAQ">IMPL</a>) stock decreased by 15.63% to $0.68. The company's market cap stands at $16.0 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock fell 13.27% to $0.16. The company's market cap stands at $5.0 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares declined by 13.14% to $1.72. The market value of their outstanding shares is at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOL

BNOX

EVOK

FWBI

IMPL

PTPI

SCNI

ZVSA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company&rsquo;s securities had closing bid price of $0.10/less for 10 consecutive trading days.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) gained 63.5% to $0.2101.</li>
<li>Rocket Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rckt#NASDAQ">RCKT</a>) rose 31.8% to $20.15 after the company announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501 for Danon Disease.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) gained 22.2% to $0.1090.</li>
<li>Axcella Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axla#NASDAQ">AXLA</a>) shares jumped 19.3% to $1.36 after jumping more than 59% on Tuesday.</li>
<li>Alset Capital Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acax#NASDAQ">ACAX</a>) gained 19.1% to $10.60.</li>
<li>Ohmyhome Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omh#NASDAQ">OMH</a>) gained 18.2% to $1.9147.</li>
<li>ECARX Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ecx#NASDAQ">ECX</a>) surged 16.8% to $3.5628.</li>
<li>VEON Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veon#NASDAQ">VEON</a>) gained 16.4% to $19.30.</li>
<li>Super League Enterprise, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sle#NASDAQ">SLE</a>) shares gained 16.2% to $2.2650 after falling 40% on Tuesday.</li>
<li>DZS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dzsi#NASDAQ">DZSI</a>) gained 15.3% to $2.11. DZS secured $29.7 million in financing.</li>
<li>HireRight Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrt#NYSE">HRT</a>) climbed 14.8% to $10.05. HireRight plans additional $25 million share repurchase program.</li>
<li>Sigma Lithium Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgml#NASDAQ">SGML</a>) rose 13.7% to $36.54.</li>
<li>Navidea Biopharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/navb#NYSE">NAVB</a>) gained 13.3% to $0.1050.</li>
<li>Workhorse Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wkhs#NASDAQ">WKHS</a>) shares rose 13.2% to $0.7199 after the company announced it has received IRS approval as a qualified manufacturer for the Commercial Clean Vehicle Credit.</li>
<li>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) gained 12.5% to $1.44.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) gained 11.5% to $0.2041 after declining 13% on Tuesday.</li>
<li>REV Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/revg#NYSE">REVG</a>) surged 9.2% to $14.07 after the company reported better-than-expected third-quarter financial results and raised FY23 net sales guidance above estimates.</li>
<li>Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) rose 6% to $3.88 after the company announced topline results from its ColoFuture study.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) shares tumbled 71% to $3.05.</li>
<li>Eiger BioPharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eigr#NASDAQ">EIGR</a>) shares dipped 52.5% to $0.3279 after the company announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta.</li>
<li>Calidi Biotherapeutics (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NYSE">CLDI</a>) fell 42.5% to $4.60 following the company&rsquo;s public debut.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) tumbled 31.3% to $2.72.</li>
<li>KULR Technology Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kulr#NYSE">KULR</a>) fell 29% to $0.4129 as the company reported pricing of $2.5 million public offering of common stock.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) fell 28.5% to $0.3950.</li>
<li>Evolution Petroleum Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/epm#NYSE">EPM</a>) fell 23% to $6.81 after reporting downbeat fourth-quarter results.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aaoi#NASDAQ">AAOI</a>) declined 19% to $9.20.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) shares fell 18.7% to $1.0887 after declining more than 20% on Tuesday.</li>
<li>Acelyrin, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slrn#NASDAQ">SLRN</a>) fell 16.6% to $10.68. Morgan Stanley downgraded Acelyrin from Overweight to Equal-Weight and lowered the price target from $39 to $19.</li>
<li>Coda Octopus Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/coda#NYSE">CODA</a>) declined 16.2% to $6.27 following downbeat quarterly results.</li>
<li>Infinity Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infi#NASDAQ">INFI</a>) tumbled 16% to $0.0707. Infinity Pharmaceuticals received a delisting determination letter from Nasdaq stating that the company&#39;s stock will be suspended on Sept. 14, unless it requests a review of this decision.</li>
<li>Nature Wood Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwgl#NASDAQ">NWGL</a>) shares fell 15.4% to $8.12. Nature Wood Group reported the pricing of its initial public offering of 750,000 American Depositary Shares at $9 per ADS.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) fell 14.7% to $11.29. GigaCloud Technology recently entered into an agreement as the stalking horse bidder to acquire substantially all assets of Noble House Home Furnishings for $85 million.</li>
<li>Nature Wood Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwgl#NASDAQ">NWGL</a>) shares declined 12% to $8.45.</li>
<li>Kaixin Auto Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kxin#NASDAQ">KXIN</a>) shares fell 9.2% to $0.2487. Kaixin Auto recently inked a non-binding acquisition term sheet with WM Motor.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) fell 9% to $5.18. Sana Biotechnology spokesperson, at Morgan Stanley Healthcare Conference, said expects to file an IND filing for SC291 product candidate in autoimmune diseases in the fourth quarter.</li>
<li>WeWork Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/we#NYSE">WE</a>) fell 7.7% to $5.21 after jumping 87% on Tuesday.</li>
<li>Roblox Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rblx#NYSE">RBLX</a>) tumbled 7.2% to $27.10.</li>
<li>Grab Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grab#NASDAQ">GRAB</a>) fell 7.2% to $3.5175 after Singapore&#39;s Land Transport Authority announced it will investigate the supply of taxi and ride-hailing services in connection with a a review of the point-to-point industry structure and regulatory framework.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 5.7% to $36.75.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/09/34536808/bitcoin-tops-26-000-toncoin-emerges-as-top-gainer"> Bitcoin Tops $26,000; Toncoin Emerges As Top Gainer</a>

AAOI

ACAX

CLDI

CODA

DZSI

EIGR

GRAB

ALPS ETF Trusthen & Steers Global Realty Majors ETF

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INFI

KULR

KXIN

MYNZ

NWGL

RBLX

RCKT

REVG

SANA

SGML

SLRN

VEON

WKHS

Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>PhenomeX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELL#NASDAQ">CELL</a>) shares increased by 136.4% to $0.95 during Thursday's regular session. As of 13:31 EST, PhenomeX's stock is trading at a volume of 19.6 million, which is 2758.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $93.9 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 59.98% to $0.11. As of 13:31 EST, this security is trading at a volume of 429.4 million shares, making up 1776.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.7 million. As per the news, the Q2 earnings report came out 3 days ago. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares moved upwards by 36.47% to $0.41. Trading volume for this security as of 13:31 EST is 9.6 million, which is 10968.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.0 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) stock increased by 22.44% to $1.2. Trading volume for this security as of 13:31 EST is 11.3 million, which is 12653.4% of its average full-day volume over the last 100 days. The company's market cap stands at $25.3 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock rose 21.31% to $0.91. Salarius Pharmaceuticals's stock is trading at a volume of 66.2K shares as of 13:31 EST. This is 114.3% of its average full-day volume over the last 100 days. The company's market cap stands at $3.3 million. </li>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock rose 16.05% to $10.73. The market value of their outstanding shares is at $235.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIOP#NASDAQ">FBIOP</a>) shares fell 24.5% to $10.01 during Thursday's regular session. Trading volume for this security as of 13:31 EST is 136.5K, which is 831.5% of its average full-day volume over the last 100 days. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares fell 23.25% to $0.14. As of 13:31 EST, Novo Integrated Sciences's stock is trading at a volume of 44.6 million, which is 291.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.6 million. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) stock decreased by 19.88% to $3.75. As of 13:31 EST, Bioventus's stock is trading at a volume of 563.6K, which is 74.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $235.4 million. </li>
<li>Navidea Biopharmaceutical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAVB#AMEX">NAVB</a>) stock decreased by 17.09% to $0.08. The current volume of 4.1 million shares is 51.7% of Navidea Biopharmaceutical's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $7.6 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) stock fell 16.69% to $0.47. Trading volume for this security as of 13:31 EST is 103.1 million, which is 104.3% of its average full-day volume over the last 100 days. The company's market cap stands at $158.0 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares declined by 15.55% to $0.13. As of 13:31 EST, Alaunos Therapeutics's stock is trading at a volume of 2.6 million, which is 267.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.7 million. As per the press release, Q2 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

ANTX

CELL

FBIOP

MODD

SLRX

TCRT

TIVC

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) stock increased by 68.6% to $0.2 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 346.2 million, which is 3787.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.0 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 59.13% to $0.06. As of 13:31 EST, this security is trading at a volume of 226.3 million shares, making up 1191.2% of its average full-day volume over the last 100 days. The company's market cap stands at $8.6 million. The company's, Q2 earnings came out 2 days ago. </li>
<li>Navidea Biopharmaceutical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAVB#AMEX">NAVB</a>) stock increased by 27.93% to $0.09. Trading volume for Navidea Biopharmaceutical's stock is 16.3 million as of 13:31 EST. This is 213.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.9 million. </li>
<li>Miromatrix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) stock rose 18.96% to $1.53. The current volume of 63.0K shares is 116.6% of Miromatrix Medical's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $41.6 million. As per the press release, Q2 earnings came out 2 days ago. </li>
<li>Catalyst Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares moved upwards by 16.21% to $0.43. As of 13:31 EST, Catalyst Biosciences's stock is trading at a volume of 835.3K, which is 152.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.3 million. </li>
<li>Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) stock rose 13.84% to $0.94. As of 13:31 EST, Star Equity Hldgs's stock is trading at a volume of 399.3K, which is 264.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $14.3 million. The company's, Q2 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMPL#NASDAQ">IMPL</a>) stock decreased by 43.6% to $0.61 during Wednesday's regular session. Trading volume for Impel Pharmaceuticals's stock is 730.1K as of 13:31 EST. This is 106.6% of its average full-day volume over the last 100 days. The company's market cap stands at $14.4 million. </li>
<li>RVL Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVLP#NASDAQ">RVLP</a>) shares declined by 41.67% to $0.24. Trading volume for RVL Pharmaceuticals's stock is 1.4 million as of 13:31 EST. This is 1601.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.3 million. The company's, Q2 earnings came out 2 days ago. </li>
<li>Mallinckrodt (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MNK#AMEX">MNK</a>) stock declined by 23.81% to $0.56. As of 13:31 EST, Mallinckrodt's stock is trading at a volume of 834.9K, which is 17.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.4 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 21.38% to $2.17. Trading volume for this security as of 13:31 EST is 1.6 million, which is 142.3% of its average full-day volume over the last 100 days. The company's market cap stands at $61.8 million. As per the news, the Q2 earnings report came out 2 days ago. </li>
<li>G Medical Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMVD#NASDAQ">GMVD</a>) shares declined by 17.95% to $0.18. Trading volume for G Medical Innovations's stock is 2.4 million as of 13:31 EST. This is 262.3% of its average full-day volume over the last 100 days. The company's market cap stands at $1.7 million. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) shares fell 16.96% to $0.25. As of 13:31 EST, PAVmed's stock is trading at a volume of 1.4 million, which is 282.9% of its average full-day volume over the last 100 days. The company's market cap stands at $26.5 million. As per the press release, Q2 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBIO

GMVD

MIRO

PAVM

RMTI

RVLP

STRR

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Yellow Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yell#NASDAQ">YELL</a>) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.</li>
<li>FOXO Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/foxo#NYSE">FOXO</a>) rose 64.7% to $0.2232.</li>
<li>Bruush Oral Care Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brsh#NASDAQ">BRSH</a>) gained 48% to $0.1979 after the company announced a 1-for-25 reverse stock split.</li>
<li>Archer Aviation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achr#NASDAQ">ACHR</a>) shares climbed 41.8% to $6.78 after the company entered into contracts with the US Air Force with a total value of up to $142 million.</li>
<li>Tupperware Brands Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tup#NYSE">TUP</a>) gained 39.6% to $4.2999 amid possible short squeeze interest.</li>
<li>Mallinckrodt plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mnk#NYSE">MNK</a>) jumped 39% to $1.51 on continued volatility following last week&#39;s reports of the company considering bankruptcy as part of a plan to avoid opioid payments.</li>
<li>GoodRx Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdrx#NASDAQ">GDRX</a>) gained 38.1% to $9.32 after TD Cowen upgraded the stock from Market Perform to Outperform and raised its price target from $6.5 to $12.</li>
<li>AEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lidr#NASDAQ">LIDR</a>) gained 34.6% to $0.3766.</li>
<li>Symbotic Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sym#NASDAQ">SYM</a>) climbed 32.3% to $55.81 after the company reported better-than-expected third-quarter results.</li>
<li>Steakholder Foods Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkh#NASDAQ">STKH</a>) gained 30.6% to $1.53.</li>
<li>T2 Biosystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttoo#NASDAQ">TTOO</a>) gained 28% to $0.1492 after the company announced it received an extension to comply with the Nasdaq listing requirements.</li>
<li>Xiao-I Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aixi#NASDAQ">AIXI</a>) gained 26.2% to $9.02.</li>
<li>iClick Interactive Asia Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclk#NASDAQ">ICLK</a>) climbed 25.8% to $3.0074.</li>
<li>Fifth Wall Acquisition Corp. III (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwac#NASDAQ">FWAC</a>) climbed 25.6% to $14.48.</li>
<li>Applied Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) gained 25.4% to $1.8684.</li>
<li>Xiao-I Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aixi#NASDAQ">AIXI</a>) rose 24.3% to $8.89.</li>
<li>China Natural Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chnr#NASDAQ">CHNR</a>) shares surged 22.8% to $2.42 after the company agreed to sell all outstanding shares of Precise Space-Time Technology Limited to Feishang Group Limited, together with PSTT&#39;s outstanding payable owed to the Company, for consideration of around RMB95,761,119 in cash.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) gained 21.1% to $2.7520. The company announced an agreement in which J.B. Hunt Transport will purchase 13 Nikola zero-emission Class 8 EV trucks.</li>
<li>Innoviz Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/invz#NASDAQ">INVZ</a>) climbed 21.1% to $4.1291 amid bullish commentary from a well-known short seller.</li>
<li>SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>) gained 20.4% to $11.49 after the company reported better-than-expected Q2 financial results, issued 2H adjusted net revenue guidance and raised FY23 adjusted net revenue guidance.</li>
<li>Canoo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goev#NASDAQ">GOEV</a>) climbed 18.6% to $0.6429.</li>
<li>fuboTV Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fubo#NASDAQ">FUBO</a>) gained 18% to $3.3150.</li>
<li>2U, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twou#NASDAQ">TWOU</a>) gained 15.5% to $4.72.</li>
<li>Barnes &amp; Noble Education, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bned#NYSE">BNED</a>) shares climbed 15.2% to $1.44 after the company entered into an agreement with key financial stakeholders and strategic partners to strengthen financial position and support growth initiatives.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffie#NASDAQ">FFIE</a>) climbed 14.5% to $0.2947.</li>
<li>Jumia Technologies AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jmia#NASDAQ">JMIA</a>) rose 14% to $4.87.</li>
<li>New Relic, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newr#NYSE">NEWR</a>) gained 13.5% to $84.03 after the company reported better-than-expected Q1 financial results and announced it will be acquired by Francisco Partners and TPG for $6.5 billion.</li>
<li>TMC the metals company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmc#NASDAQ">TMC</a>) gained 13.4% to $1.6450.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) rose 13% to $9.26.</li>
<li>AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>) gained 13% to $19.34. AnaptysBio, said that GSK has received U.S. Food and Drug Administration approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eose#NASDAQ">EOSE</a>) rose 12.2% to $2.5350. Eos Energy Enterprises said it expects to record revenue of $0.2 million for the quarter ended June 30, 2023.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) gained 11.5% to $4.6950.</li>
<li>Affirm Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afrm#NASDAQ">AFRM</a>) rose 11.2% to $19.20.</li>
<li>Palantir Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) climbed 10.1% to $19.61 on continued upward momentum after Wedbush on Friday initiated coverage on the stock with an Outperform rating and announced a $25 price target.</li>
<li>Aurora Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aurc#NASDAQ">AURC</a>) gained 9.9% to $48.36 after jumping 113% on Friday</li>
<li>Roku, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roku#NASDAQ">ROKU</a>) gained 7.5% to $96.41 on continued strength after the company last week reported better-than-expected Q2 results and issued strong Q3 guidance.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) rose 7.1% to $19.61 after the company announced record admissions revenue for the week of July 21-27.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) climbed 6.3% to $5.05.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alset Capital Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acax#NASDAQ">ACAX</a>) shares fell 27.9% to $5.50.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) dipped 26.5% to $10.58.</li>
<li>BioNexus Gene Lab Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bglc#NASDAQ">BGLC</a>) fell 25.3% to $2.24 after jumping over 40% on Friday.</li>
<li>Unique Fabricating, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ufab#NYSE">UFAB</a>) fell 24.7% to $0.2601 after gaining 60% on Friday.</li>
<li>Silicom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silc#NASDAQ">SILC</a>) dropped 24.6% to $29.45 after the company reported lower-than-expected second-quarter results.</li>
<li>Birks Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bgi#NYSE">BGI</a>) fell 20.1% to $3.3172.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) fell 18.8% to $26.00 after the company reported quarterly financial results.</li>
<li>Marker Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrkr#NASDAQ">MRKR</a>) declined 18.7% to $5.26.</li>
<li>Tigo Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tygo#NASDAQ">TYGO</a>) fell 17.8% to $20.50.</li>
<li>TeraWulf Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wulf#NASDAQ">WULF</a>) declined 14.3% to $2.9288.</li>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) fell 13% to $0.5655 after dipping over 22% on Friday.</li>
<li>Citius Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctxr#NASDAQ">CTXR</a>) fell 11.3% to $0.9936 after the company received FDA Complete Response Letter for Lymphir (Denileukin Diftitox) for relapsed/refractory cutaneous T-cell lymphoma.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) dropped 11% to $20.82 after UBS downgraded the stock from Buy to Neutral.</li>
<li>Navidea Biopharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/navb#NYSE">NAVB</a>) fell 10.4% to $0.0849 after the company announced NYSE American has commenced delisting proceedings and the company intends to appeal.</li>
<li>Pulse Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plse#NASDAQ">PLSE</a>) fell 7.4% to $8.00.</li>
<li>Bel Fuse Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/belfb#NASDAQ">BELFB</a>) fell 7.1% to $53.47.</li>
<li>DexCom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxcm#NASDAQ">DXCM</a>) declined 5.7% to $124.62 amid a pullback in the stock following earlier strength.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/07/33469316/huntsman-likely-to-post-sharp-decline-in-q2-earnings-heres-a-look-at-recent-price-target-changes-by"> Huntsman Likely To Post Sharp Decline In Q2 Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

ACHR

AFRM

AIXI

ANAB

APLS

APLT

AURC

BELFB

BGLC

BNED

BRSH

CHNR

CTXR

DXCM

FFIE

FOXO

FUBO

FWAC

GDRX

GOEV

ICLK

IHRT

INVZ

JMIA

LIDR

MRKR

NEWR

NKLA

NVAX

PLSE

PLTR

ROKU

SILC

SOFI

STKH

TWOU

TYGO

UFAB

VIEW

WULF

XPEV

YELL

Why Apellis Pharmaceuticals  Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session

Navidea Biopharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/navb#NASDAQ">NAVB</a>) shares are trading lower by 18.5% to $0.08 after the company announced&nbsp;NYSE American has commenced delisting proceedings and the company <a href="https://www.benzinga.com/pressreleases/23/07/b33452983/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-int">intends to appeal</a>.
Navidea&#39;s Board of Directors plans to appeal the decision. During the appeal, the common stock will continue to be listed and traded on NYSE American.
The company says there can be no assurance that Navidea&#39;s request for continued listing will be granted.
If delisted, Navidea intends to quote its common stock in the over-the-counter market.
See Also:&nbsp;<a href="https://www.benzinga.com/news/earnings/23/07/33466876/why-aercap-shares-are-rising-today">Why AerCap Shares Are Rising Today</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NAVB has a 52-week high of $0.65 and a 52-week low of $0.07.

Why Navidea Biopharmaceuticals Shares Are Nosediving

Following the Company&#39;s Fix, Fund, Propel approach, Navidea continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from the New York Stock Exchange (NYSE).
Navidea Biopharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAVB#NYSE">NAVB</a>) (&quot;Navidea&quot; or the &quot;Company&quot;), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its continued and steadfast focus on moving the Company forward and leveraging its Fix Fund Propel approach while also intending to appeal potential delisting from the NYSE American Exchange.
&quot;Although the traditional exchange has been a part of Navidea&#39;s history and may be in the future, our strategy and approach remains resolute in the face of change,&quot; said Josh Wilson, Director. &quot;The Company&#39;s progress is clear, and the impact of the changes we have made will continue to move us forward. Navidea will continue to focus on using our Fix, Fund Propel approach, our strategic vision to advance Navidea&#39;s innovative technology to market, and the delivery of value to our stockholders.&quot;
Clear Progress Continues
The Company&#39;s Board and leadership team, together with G2G Ventures as executive consultants, set a course to implement strategic planning and change initiatives to drive effective processes, improve liquidity, and create growth - the Company&#39;s Fix, Fund, Propel framework and approach. This approach continues to deliver the intended results and drive the organization forward.
<ul>
<li>(Fix) Selling, general and administrative expenses were down&nbsp;36%&nbsp;in the&nbsp;first quarter&nbsp;of 2023, compared to the same period in 2022.</li>
<li>(Fix) Michael Blue, M.D., FACEP was promoted to Chief Medical Officer to lead the continued development of the Company&#39;s initiatives in innovative diagnostics and therapeutics, and advance the Company&#39;s NAV3-32 and NAV3-33 clinical trials to completion.</li>
<li>(Fix) Simon Alder Blackburn, CCRA was promoted to Associate Director of Clinical Research and Operations, with responsibility for supervising providers and recommending and implementing product development, corporate strategy, and marketing initiatives.</li>
<li>(Fix) Craig A. Dais, CPA, was hired as Chief Financial Officer, strengthening the Company&#39;s financial expertise and oversight with demonstrated expertise in accounting, financial modeling, capital development, and strong growth-oriented leadership within private and publicly-held organizations.</li>
<li>(Fix) Jill Bieker Stefanelli, Ph.D., and Dana J Moss, JD, joined the Company&#39;s Board of Directors, adding deep experience across several important disciplines and helping improve the Company&#39;s ability to develop and advance precision medicine products and innovative technology to market.</li>
<li>(Fund) The Company entered into a Common Stock Purchase Agreement with Keystone Capital Partners, LLC whereby Keystone committed to purchase up to&nbsp;$2,750,000&nbsp;of shares of the Company&#39;s common stock.</li>
<li>(Fund) The Company entered into an amendment to an Asset Purchase Agreement between the Company and Cardinal Health 414, LLC to receive&nbsp;$7.5 million&nbsp;in cash, in exchange for waiving certain rights, providing immediate capital for the Company&#39;s Phase IIb (NAV3-32) and Phase III (NAV3-33) trials and related operations and building on a history of partnership between the Company and Cardinal Health.</li>
<li>(Fund) The Company announced the sale of&nbsp;$1.1 million&nbsp;in preferred shares to two investors, providing additional capital to advance the Company&#39;s NAV3-32 and NAV3-33 clinical trials toward completion.</li>
<li>(Fund/Propel)The Company entered into an Asset Purchase Agreement with Meilleur Technologies, Inc., pursuant to which Meilleur agreed to acquire certain assets and assume certain liabilities of the Company relating to its business of developing and commercializing PET biomarkers for Alzheimer&#39;s Disease. As part of the purchase, Meilleur paid a cash payment of&nbsp;$250,000&nbsp;to the Company at closing and agreed to make a cash payment of&nbsp;$500,000&nbsp;to the Company within 60 days after the closing date. In addition, certain future payments may be made to the Company, including contingent payments and milestone payments based on potential licensing events, regulatory submissions, regulatory approvals, and net sales of any approved product derived from the purchased business.</li>
<li>(Fund/Propel) The Company launched its Strategic Partnership Initiative focused on developing long-term licensing revenue opportunities in&nbsp;Q3&nbsp;2023.</li>
</ul>
Change Creates Opportunity
While the traditional exchange has been an integral part of Navidea&#39;s history, and the Company intends to appeal the potential delisting, its Fix, Fund Propel approach and focus would not change as a result of a transition from the Exchange. Instead, the Company may embrace potential new opportunities to deliver exceptional value to our stakeholders, including:
<ul>
<li>Diverse Sources of Capital&nbsp;- The Company now has the unique advantage of exploring and more quickly tapping into a broader spectrum of capital sources tailored to Navidea&#39;s specific growth needs, ensuring the financial resources required to achieve its strategic objectives.</li>
<li>Strategic Agility&nbsp;- As Navidea continues pursuing its ambitious Fix, Fund, Propel, approach, this transition allows the Company to operate with increased agility, removed from the constraints of short-term pressure, enabling focus on executing initiatives that drive growth in the market.</li>
</ul>
Company Studies and Trials Update
<ul>
<li>NAV3-32 -&nbsp;The trial is nearly complete. NAV2-32 has 18 completed patients, defining 3 types of RA, and has met the minimum number of patients in 2 of the 3 RA types. Ongoing and accelerated enrollment results will support the completion of the third RA basket and trial.</li>
<li>NAV3-33 -&nbsp;Currently, the Company supports 15 active sites (up from 12 in&nbsp;Q2) which are open, screening and enrolling subjects. The Company Clinical Site Plan includes adding up to an additional 15 sites over the next 90 days. Currently, the Company has 102 Subjects enrolled.</li>
</ul>
Propelling the Company Forward
The Company is focused on driving shareholder return through the successful completion of Phase 2b and Phase 3 clinical trials. This includes sourcing efficient capital to expand and deliver innovative technology and drug applications to the market. The powerful combination of innovation and execution is designed to improve market awareness and market confidence while driving shareholder return.
&quot;Our vision is clear. Our team and our Board are relentlessly focused on achieving our goals for our future,&quot; said Michael Blue, M.D., FACEP, Navidea&#39;s Chief Medical Officer. &quot;Our journey and our focus is to advance innovative technology to market, and to deliver value to our stockholders.&quot;

Management

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares increased by 26.6% to $3.33 during Monday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>Better Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTTX#NASDAQ">BTTX</a>) shares moved upwards by 16.93% to $0.72. The market value of their outstanding shares is at $24.4 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock rose 11.76% to $0.95. The company's market cap stands at $122.4 million. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock moved upwards by 11.23% to $2.97. The company's market cap stands at $375.7 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares rose 10.34% to $0.13. The market value of their outstanding shares is at $3.1 million. </li>
<li>Calliditas Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) stock rose 10.32% to $19.98. The market value of their outstanding shares is at $536.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Checkpoint Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) shares declined by 16.1% to $2.6 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. </li>
<li>Citius Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares fell 14.69% to $0.96. The company's market cap stands at $151.7 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock declined by 13.19% to $1.91. The company's market cap stands at $48.7 million. </li>
<li>Navidea Biopharmaceutical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAVB#AMEX">NAVB</a>) stock decreased by 10.64% to $0.08. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock fell 7.93% to $0.31. The company's market cap stands at $10.4 million. </li>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) shares decreased by 6.98% to $0.72. The market value of their outstanding shares is at $29.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

BTTX

CALT

CKPT

CMPX

OKYO

PLUR

SONN

XTNT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>China Natural Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chnr#NASDAQ">CHNR</a>) shares surged 63.5% to $3.22 in pre-market trading after the company agreed to sell all outstanding shares of Precise Space-Time Technology Limited to Feishang Group Limited, together with PSTT&#39;s outstanding payable owed to the Company, for consideration of around RMB95,761,119 in cash.</li>
<li>FOXO Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/foxo#NYSE">FOXO</a>) rose 45.3% to $0.1941 in pre-market trading.</li>
<li>Aurora Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aurc#NASDAQ">AURC</a>) gained 29.6% to $57.08 in pre-market trading after jumping 113% on Friday</li>
<li>Nano Labs Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/na#NASDAQ">NA</a>) shares gained 25% to $1.80 in pre-market trading after the company reported receipt of interest-free loans from shareholders.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) shares rose 18% to $0.1533 in pre-market trading.</li>
<li>Inpixon (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inpx#NASDAQ">INPX</a>) shares gained 16.6% to $0.2814 in pre-market trading after jumping 19% on Friday.</li>
<li>Barnes &amp; Noble Education, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bned#NYSE">BNED</a>) shares climbed 16% to $1.45 in pre-market trading after the company entered into an agreement with key financial stakeholders and strategic partners to strengthen financial position and support growth initiatives.</li>
<li>Visionary Education Technology Holdings Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vedu#NASDAQ">VEDU</a>) shares rose 14.5% to $0.4479 in pre-market trading after gaining 5% on Friday.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) gained 13.9% to $36.47 in pre-market trading after the company issued an update on review of rare safety events with Syfovre for geographic atrophy.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eose#NASDAQ">EOSE</a>) rose 11.5% to $2.52 in pre-market trading. Eos Energy Enterprises said it expects to record revenue of $0.2 million for the quarter ended June 30, 2023.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Navidea Biopharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/navb#NYSE">NAVB</a>) fell 22.4% to $0.0737 in pre-market trading after the company announced NYSE American has commenced delisting proceedings and the company intends to appeal.</li>
<li>Unique Fabricating, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ufab#NYSE">UFAB</a>) fell 17.6% to $0.2850 in pre-market trading after gaining 60% on Friday.</li>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sonn#NASDAQ">SONN</a>) fell 16.3% to $0.2850 in pre-market trading. Sonnet BioTherapeutics, last month, announced a $2.25 million registered direct offering of 5 million at $0.45/share.</li>
<li>Troika Media Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trka#NASDAQ">TRKA</a>) shares fell 9.7% to $2.33 in pre-market trading after gaining over 7% on Friday.</li>
<li>Citius Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctxr#NASDAQ">CTXR</a>) fell 9% to $1.02 in pre-market trading after the company received FDA Complete Response Letter for Lymphir (Denileukin Diftitox) for relapsed/refractory cutaneous T-cell lymphoma.</li>
<li>Satixfy Communications Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/satx#NASDAQ">SATX</a>) shares fell 9.6% to $0.2985 in pre-market trading. SatixFy Communications recently named Mr. Nir Barkan as Acting Chief Executive Officer.</li>
<li>BioNexus Gene Lab Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bglc#NASDAQ">BGLC</a>) fell 8.7% to $2.74 in pre-market after jumping over 40% on Friday.</li>
<li>Akari Therapeutics, Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aktx#NASDAQ">AKTX</a>) fell 8.2% to $0.2001 in pre-market trading. Akari Therapeutics was recently granted Nomacopan Orphan Drug Designation from the European Commission for treatment in hematopoietic stem cell transplantation.</li>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) shares fell 6.8% to $0.4685 in pre-market trading.</li>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) fell 6.8% to $0.6061 in pre-market trading after dipping over 22% on Friday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/07/33465358/market-volatility-falls-following-june-pce-data-s-p-500-settles-higher"> Market Volatility Falls Following June PCE Data; S&amp;P 500 Settles Higher</a>

AKTX

GBNH

INPX

SatixFy Communications Ltd. Ordinary Share

SATX

TRKA

Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket

Comments

Navidea Biopharmaceutical

Navidea Biopharmaceutical (NAVB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO